Zai Lab (Shanghai) Co., Ltd.

Quick facts

Phase 3 pipeline

• Investigator's Choice of Therapy
  Investigator's Choice of Therapy is a flexible treatment approach where the treating physician selects from approved or standard-of-care therapeutic options based on individual patient characteristics.
• ZL-1109 (VRDN-003) · Oncology
  ZL-1109 (VRDN-003) is a small molecule targeting the PD-1 receptor.
• ZL-1310 · Oncology
  ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

Phase 2 pipeline

• Brivanib 400 mg, BID · Oncology
  Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.
• Brivanib 800 mg, QD · Oncology
  Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.

Phase 1 pipeline

• Margetuximab Margetuximab-IV
• ZL-1201
• ZL-1503
• ZL-6201

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zai Lab (Shanghai) Co., Ltd. portfolio CI brief
• Zai Lab (Shanghai) Co., Ltd. pipeline updates RSS